Colorectal cancer and the KIR genes in the human genome: A meta-analysis  by Ghanadi, Koroush et al.
Genomics Data 10 (2016) 118–126
Contents lists available at ScienceDirect
Genomics Data
j ourna l homepage: www.e lsev ie r .com/ locate /gdataColorectal cancer and the KIR genes in the human genome:
A meta-analysisKoroush Ghanadi a, Bahareh Shayanrad b,c, Seyyed Amir Yasin Ahmadi c, Farhad Shahsavar b,⁎, Hossein Eliasy d
a Department of Internal Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
b Department of Immunology, Lorestan University of Medical Sciences, Khorramabad, Iran
c Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran
d Research Ofﬁce for the History of Persian Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran⁎ Corresponding author.
E-mail address: farhad.shahsavar@lums.ac.ir (F. Shahs
http://dx.doi.org/10.1016/j.gdata.2016.10.010
2213-5960/© 2016 Published by Elsevier Inc. This is an opa b s t r a c ta r t i c l e i n f oArticle history:
Received 13 September 2016
Received in revised form 21 October 2016
Accepted 30 October 2016
Available online 1 November 2016Colorectal cancer is one of themost common types of inﬂammation-based cancers and is occurred due to growth
and spread of cancer cells in colon and/or rectum. Previously genetic association of cell cycle genes, both proto-
oncogenes and the tumor suppressors has been proved. But therewere few studies about association of immune
related genes such as killer-cell immunoglobulin-like receptors (KIRs). Thus we intend to perform a meta-analysis
to ﬁnd the association of different genes of KIR and susceptibility to be affected by colorectal cancer. The overall
population of the four studies investigated in our meta-analysis was 953 individuals (470 individuals with colo-
rectal cancer and 483 individuals in control groups). After the analyses, we concluded that colorectal cancer is af-
fected by KIR2DS5 and also there were no protecting gene. This result shows the inﬂammatory basis of this
cancer. In other words, in contrast to leukemia and blood cancers, colorectal cancers seem to be affected by
hyper activity of natural killer-cells (NKs). Whys and therefore of this paradox, is suggested to be investigated
further.avar).
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Meta-analysis1. Introduction
Themost common cancer inmales is the prostate [1] cancerwhereas
themost common cancer andmalignancy in female is the breast cancer
[2–5]. Among cancers, colorectal and lung cancers are of themostwide-
spread cancers in both genders [1]. So colorectal cancer has a strategic
importance for governments. Although other cancers like ovarian and
endometrial cancers are also prevalent in women [6,7], but the strategic
importance of colorectal cancers is higher mortality and affecting both
genders.
Colorectal disease like Crohn's disease and ulcerative colitis has very
strategic importance from the epidemiological points of view [8] aswell
as colorectal cancers. Colorectal cancer is one of themost common types
of cancers, particularly in developed countries and it is deﬁned as
growth and spread of cancer cells in colon or rectum [9]. This disease
usually has no speciﬁc symptom and often diagnose in latest and dan-
gerous stages of the disease. Most important symptoms are blood exis-
tence in stool, weight loss and permanent fatigue [10,11]. The cause of
getting this cancer is related to lifestyle, age and gender (men will get-
ting this cancer more than women) because of obesity, alcohol con-
sumption, high consumption of red meat, absence of ﬁbers in diet,
physical inactivity and especially tobacco abuse [12–14]. Increasingess article under the CC BY-NCage also has a signiﬁcant impact on the risk of this cancer so that a lot
of people over 70 years of age in Western societies gett adenoma and
adenoma increases the possibility of getting this cancer [15,16]. This dis-
ease has several stages. In theﬁrst stage, cancer cells are in inner layer of
colon or rectum, in the next stage the cancer spreads in muscular layer
of colon or rectum, thereafter in a next stage, the cancer enter to a few
lymph nodes in the same area and after that in another stagemetastasis
occurs and the cancer spreads into other tissues and body areas; at this
stage the disease is usually not curable [17–19]. Most colorectal cancers
originate from the benign adenomas that forms in colon. Molecular and
genetic studies indicate that about 70% of colorectal cancers arise by
mutation and inactivation of the gene adenomatous polyposis coli
(APC) and other tumors arising as a result of activating mutations in
the genes that producing beta-catenin and axin [16,20–22]. Also other
genetic studies have shown that this cancer usually arises due to the
mutations that cause instability of some chromosomes and change the
structure of these chromosomes. These chromosomal changes cause
not to produce an enough number of copies of the tumor suppressors
like APC and P53 [23–28]. Other than tumor suppressor genes, this and
some other cancers can be affected by proto-oncogenes like the ubiqui-
tin-like with PHD and ring-ﬁnger domains 1 (UHRF1) [29]. Other re-
searches have indicated that mutation in KRAS and epidermal growth
factor (EGF) signaling pathways have an important role in getting this
cancer [30,31].
Immune system responses have important role in controlling and
preventing development of colorectal cancers [26]. Colorectal cancer-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
KIR genes. KIR has 14 discovered genes and 2 discovered pseudo-genes. Seven number of them are inhibitory, 1 of them is
both inhibitory and activating and 6 number them are activating. Each gene has different alleles; So KIR is highly polymor-
phic like HLA.
KIR genes
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genes
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2
2DL
3
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1
119K. Ghanadi et al. / Genomics Data 10 (2016) 118–126cells have several antigens which recognized by immune system.
Among these antigens, Carcinoembryonic antigen (CEA) is the most
studied [32,33]. In addition, several neo-antigens were detected in
these tumor cells. These neo-antigens are the cause of high levels of
lymphocytes inﬁltrating to the tumor cells [23]; so the cancer progres-
sion can be diagnosed from the level of lymphocyte inﬁltration. Since
generally the cancerous cells fail to express human leukocyte antigen
(HLA) class I and therefore bypass cytotoxic T lymphocytes, natural kill-
er-cells (NKs) as important components of the innate immune system,
play a key role in this condition [34]. Killer cell immunoglobulin-like re-
ceptors (KIRs) (also called as CD158) are polymorphic glycoproteins
expressed on cell surface of NKs and T cell subsets [35]. KIR gene family
is highly polymorphic and its genomic diversity is achieved throughFig. 1. Colorectal cancer is not statistically affected or protected by the KIR
Table 2
Data and meta-analysis. The ED stands for effective direction and the nagative and possitive ea
Gene Middleton et al. [58] Beksac et al. [60] Al Om
Cancer N = 90 Control N = 100 Cancer N = 87 Control N = 154 Cance
2DL1 86 94 77 147 51
2DL2 61 57 68 103 47
2DL3 69 85 48
2DL4 52
2DL5 50 52 45
3DL1 83 91 51
3DL2 52
3DL3 50
2DS1 36 39 40 75 43
2DS2 61 58 54 103 46
2DS3 29 34 34 52 40
2DS4 82 91 51
2DS5 34 26 35
3DS1 34 39 35 76 43
2DP1 52
3DP1 52
⁎⁎⁎⁎ Signiﬁcance at P b 0.05 level.differences in gene content as well as allelic polymorphism [36,37]. Of
course the most polymorphic loci in human genome is HLA [38] which
the molecules of its, are in direct contact with KIR molecules. Hereby
we intend to investigate the role of the KIR genes in colorectal cancer
as a meta-analysis to ﬁnd the association of different genes of KIR and
susceptibility to be affected by colorectal cancer.
2. Material and methods
The present study is a meta-analysis which approximately covers all
the original studies on this topic done before. We searched in databases
such as google scholar, science direct and Pubmed. Totally six papers
were found that four of them had same protocols.2DL1. Left side (the favours A) shows protecting effect in all ﬁgures.
ch one respectively means protective effect and risk factor.
ar et al. [61] Kim et al. [57] Meta-analysis
r N = 52 Control N = 70 Cancer N = 241 Control N = 159 P value (ED)
70 241 159 0.32 (−)
55 27 20 0.07 (+)
56 240 159 0.99 (+)
70 241 159 Excluded
53 107 59 0.09 (+)
66 229 156 0.45 (−)
70 241 159 Excluded
70 241 159 Excluded
25 106 56 0.28
50 31 31 0.09 (−)
40 32 29 0.81 (+)
70 229 156 0.41 (−)
22 80 33 0.0001(+)****
16 99 56 0.18 (+)
70 241 159 Excluded
70 241 159 Excluded
Fig. 2. Colorectal cancer is not statistically affected or protected by the KIR2DL2.
120 K. Ghanadi et al. / Genomics Data 10 (2016) 118–126The overall population of this four studies consists of 953 individuals
(470 individuals with colorectal cancer and 483 individuals in control
groups). The test chi-squared 2 multiplied by 2 with Yate's correction
was used to assay each gene separately. Then the results were imported
into the software comprehensive meta-analysis version 2. The 5 genes
2DL4, 3DL2, 3DL3, 2DP1 and 3DP1 were excluded from test because of
their persistence in all participants of the both groups.
3. Results
3.1. About KIR
Depending on the number of extracellular immunoglobulin do-
mains, KIRs are divided into two distinct groups (2D or 3D). TwoFig. 3. Colorectal cancer is not statistically
Fig. 4. Colorectal cancer is not statisticallytypes of KIR, i.e. inhibitory and activating, have been distinguished
based on length of the intracellular domain. Inhibitory KIRs (iKIRs) are
characterized by a long intra-cytoplasmic tail (denoted by an ‘L’ in
their name) and presence of at least one immunoreceptor tyrosine-
based inhibitory motif (ITIM). Activating KIR (aKIR) are characterized
by a short intra-cytoplasmic tail (denoted by an ‘S’ in their name) and
the absence of ITIM [37].
Up to now, fourteen distinct types of KIR have been identiﬁed in the
human genome [39]. NKs are a subset of lymphocytes comprising
around 10–15% of total lymphocytes in peripheral blood [40]. NKs prin-
cipally contribute to innate immunity and also adaptive immune re-
sponses by killing the targeted cells of theirs and production of a
variety of cytokines and chemokines [37]. Overall, upon interaction
with their ligands which are usually HLA class I, KIR provide inhibitoryaffected or protected by the KIR2DL3.
affected or protected by the KIR2DL5.
Fig. 5. Colorectal cancer is not statistically affected or protected by the KIR3DL1.
121K. Ghanadi et al. / Genomics Data 10 (2016) 118–126or activating signals to regulate the activity of NKs, which contributes to
pathogenesis of diverse kinds of diseases [41,42]. Different compounds
of KIR-HLA genotypes can induce different thresholds of activation in
NK family and such genotypic variations have been found to be associ-
ated with a number of human diseases and complications including
viral infections, autoimmune disorders and cancers [43] as well as re-
production abnormalities [44,45]. The KIR gene cluster on chromosome
19q13.4 within the leukocyte receptor complex (LRC) consists of aFig. 6. KIR2DS1. The arrowed populatio
Fig. 7. KIR2DS1meta-graph, before excentromeric and telomeric region [46]. So far, 14 KIR genes and 2
pseudogenes have been described [47] (Table 1). Seven genes of
KIR3DL1-3, KIR2DL1-3 and KIR2DL5 encode for the inhibitory KIR
(iKIR), six genes of KIR3DS1 and KIR2DS1-5 encode for activating KIRs
(aKIR), one gene encodes for KIR2DL4 with both inhibitory and activat-
ing functions, but more of inhibitory, and two genes of KIR2DP1 and
KIR3DP1 are pseudogenes that do not encode a functional KIR molecule
[47].n in for the study of Al Omar et al.
clusion of Al Omar's et al. study.
Fig. 8. KIR2DS1meta-graph, after exclusion of Al Omar's et al. study.
122 K. Ghanadi et al. / Genomics Data 10 (2016) 118–126About NK subsets, we have mainly CD16+CD56dim and CD16−-
CD56bright; the dim formhasmore cytotoxic capacity called as “cytotox-
ic NK” and the bright form contributes in secretion of inﬂammatory
cytokines called as “immune-regulatory NK”. Both of them express
KIR, but the dim form express more. [35,37,44,46,48–52].
The KIR gene cluster is ﬂanked by KIR3DL3 at centromeric end and
KIR3DL2 at telomeric end; both ofwhich are present on virtually all hap-
lotypes. Two groups of KIR haplotypes have been deﬁned on the basis of
gene content and are termed as haplotypes A and B. The A haplotypes
are uniform in terms of gene content and the most prevalent form ofFig. 9. Colorectal cancer is not statistically
Fig. 10. Colorectal cancer is not statisticallythem is composed of ﬁve inhibitory genes (KIR2DL1, 2DL3, 3DL1, 3DL2
and 3DL3), one activating gene (KIR2DS4), and the KIR2DL4 which
may have both inhibitory and activating capacity. Interestingly, many
A haplotypes possess null variants of both KIR2DS4 and KIR2DL4 that
are not expressed on the cell surface. Thus these haplotypes technically
possess no functional aKIR gene. The B haplotypes contain variable
numbers of activating and inhibitory genes and are the primary contrib-
utors to the extraordinary differences in KIR gene proﬁles observed in
distinct ethnic populations across theworld. The interaction of inhibito-
ry KIR with HLA class I as their ligands, triggers the signals that turn offaffected or protected by the KIR2DS2.
affected or protected by the KIR2DS3.
Fig. 11. Colorectal cancer is not statistically affected or protected by the KIR2DS4.
123K. Ghanadi et al. / Genomics Data 10 (2016) 118–126the NKs. Therefore, by expressing HLA-A, -B and -C molecules, healthy
cells are protected against NK lysis. Down-regulation of HLA class I ex-
pression due to tumor transformation or viral infection permits NKs to
lyse these unhealthy targeted cells of theirs, a phenomenon ﬁrst de-
scribed as the “missing-self” hypothesis. Thus the compound KIR-HLA
genotypes that lead to lower inhibition and higher activation appear
to be beneﬁcial in resistance to viral infections and cancers. On the
other hand, these dominant activating genotypes may constitute a risk
for susceptibility to autoimmune and inﬂammatory diseases [43].Fig. 12. KIR2DS5 meta-graph. Even with exclusion of the study of Al Omar's et al., the P value
Fig. 13. KIR3DS1 and that st3.2 KIR and colorectal cancer
As a general rule NKs play a key role against the cancerous cells es-
caped from toxic activity of T cells. So the KIRs expressed on surface of
NKs become important. We know that the interaction KIR-HLA has
two sides of KIR and HLA. For example overexpression of HLA-E on sur-
face of colorectal cancer cells can result in inhibition of NKs [53] and
such patients have better survival from the disease [54]; of course the
receptor of HLA-E is CD94/NKG2a [55,56]. KIR2DL1 and 2DS1 interactwould be as 0.003. For this gene, the mentioned study did not have an odds ratio bias.
udy of Al Omar's et al.
Fig. 14. KIR3DS1meta-graph, before exclusion of Al Omar's et al study.
124 K. Ghanadi et al. / Genomics Data 10 (2016) 118–126with HLA-C2, and KIR2DL2, 2DL3 and 2DS2 interact with HLA-C1 [57];
so every mathematical predict do not occur. Although at the ﬁrst glance
it seems that inhibitory types of each or both sides may be associated
with themore susceptibility, but this rule is not true for such inﬂamma-
tion-based cancers. Thewhys and therefore of this paradox, is not clear;
however there are some good data in study of Middleton et al. [58]
about loss of HLA expression in colorectal cancer cells giving us insight.
Also role of allograft inﬂammatory factor 1 (Alf1) shows the inﬂamma-
tion base of this disease [59].
Although the most inhibitory effect is attributed to the interaction
KIR2DL1-HLA-C2 [57], but none of our analyzed studies do not show
any signiﬁcant protective effect. Of course we reanalyzed previous arti-
cles' data with Yate's correction; so the relation of some genes in some
studies were signiﬁcant in the study of theirs without Yate's correction.
For example Beksac et al. [60] had been found a signiﬁcant protective ef-
fect for KIR2DL1 as we did not found so (Fig. 1).
Among the four studies analyzed by us (Table 2), the three genes 2DL4,
3DL2 and 3DL3, and both pseudogenes were present in approximately all
participants of the studies, so these genes were excluded from our meta-
analyses. Among the other genes, at ﬁrst, themeta-analyses showed a sig-
niﬁcant association for the genes 2DS1, 3DS1 and 2DS5 (Figs. 1–15); but
because of high odds ratio of study of Al Omar et al. in Saudi Arabia [61]
for the genes 2DS1 and 3DS1 (Figs. 6, 13), we were supposed to exclude
it from the analysis of these two genes. After the exclusion, only associa-
tion of KIR2DS5 remained signiﬁcant (Figs. 7, 8, 12, 14, 15).
Another justiﬁcation for this paradox is different basis of different
cancers. As we published before, breast cancer is affected by KIR2DL2Fig. 15. KIR3DS1meta-graph, after exwhich is an inhibitory gene [62]. In verse, colorectal cancer is affect-
ed by an activating KIR as we found in the present meta-analysis. Al-
though at the ﬁrst glance it seems that inhibitory interactions of KIR-
HLA may be associated with the more susceptibility to colorectal
cancer because of this fact that NKs play a key role against the can-
cerous cells escaped from toxic activity of T cells because of their
loss of HLA expression, but this rule is not true for such inﬂamma-
tion-based cancers.
Other than the justiﬁcation above, another justiﬁcation is that the li-
gands of activating KIRs are not necessarily HLAs; rather, they are still
unknown [36,53]. This, can be pointed out as the limitation of the previ-
ous studies.4. Conclusion
Finally we concluded that colorectal cancer is affected by KIR2DS5
and also therewere noprotecting gene. This result shows the inﬂamma-
tory basis of this cancer. In other words, in contrast to leukemia and
blood cancers, colorectal cancers seem to be affected by hyper activity
of natural killer-cells (NKs). Whys and therefore of this paradox, is sug-
gested to be investigated further.Conﬂict of interest
We declare that there is no conﬂict of interest.clusion of Al Omar's et al study.
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